Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Consolidated Standalone

Cipla

₹1358.8 -26 | 1.9%

Market Cap ₹109709 Cr.

Stock P/E 29.6

P/B 4.2

Current Price ₹1358.8

Book Value ₹ 320.7

Face Value 2

52W High ₹1519

Dividend Yield 0.63%

52W Low ₹ 897.7

Edit Ratio

Cipla Research see more...

Overview Inc. Year: 1935Industry: Pharmaceuticals & Drugs

Cipla Limited is an primarily India-based enterprise, usually engaged in the commercial enterprise of pharmaceuticals. The Company's segments consist of Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in growing, manufacturing, promoting and distributing widespread or branded accepted medicines, in addition to Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a customer healthcare, Biosimilars and distinctiveness enterprise. Its product portfolio spans complex generics, as well as drugs within the breathing, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The Company's geographical segments include India, America, South Africa and Rest of the World. The Company has its community of manufacturing, buying and selling and different incidental operations in India and International markets. The Company has total of 46 manufacturing sites.

Read More..

Cipla Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Cipla Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 5520 5479 5260 5375 5829 5810 5739 6329 6678 6604
Other Income 61 91 64 103 123 114 135 136 176 185
Total Income 5580 5570 5324 5479 5951 5925 5874 6465 6854 6788
Total Expenditure 4294 4248 4511 4232 4526 4403 4566 4835 4944 4856
Operating Profit 1287 1322 814 1247 1425 1522 1308 1630 1910 1932
Interest 38 21 18 18 26 32 34 16 26 30
Depreciation 253 247 290 254 299 272 346 239 290 233
Exceptional Income / Expenses 0 0 -58 0 0 0 -182 0 0 -195
Profit Before Tax 996 1054 448 975 1100 1218 745 1375 1594 1474
Provision for Tax 284 295 71 268 303 410 222 378 438 405
Profit After Tax 712 759 377 707 798 808 523 997 1156 1069
Adjustments -1 -30 -15 -20 -9 -7 3 -1 -25 -13
Profit After Adjustments 711 729 362 686 789 801 526 996 1131 1056
Adjusted Earnings Per Share 8.8 9 4.5 8.5 9.8 9.9 6.5 12.3 14 13.1

Cipla Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 8279 10173 11345 13595 14394 15156 16362 17132 19160 21763 22753 25350
Other Income 222 265 166 208 229 358 477 369 270 322 512 632
Total Income 8501 10439 11511 13803 14623 15513 16839 17501 19429 22085 23265 25981
Total Expenditure 6081 8040 9184 11115 11919 12329 13265 13951 14911 17251 17763 19201
Operating Profit 2420 2398 2327 2688 2704 3184 3574 3550 4518 4834 5502 6780
Interest 34 146 168 207 159 114 168 197 161 106 110 106
Depreciation 330 373 505 754 1323 1323 1326 1175 1068 1052 1172 1108
Exceptional Income / Expenses 40 0 0 0 0 -78 0 0 0 -182 -182 -377
Profit Before Tax 2095 1880 1654 1727 1222 1669 2079 2178 3290 3493 4038 5188
Provision for Tax 544 463 400 332 180 250 570 631 889 934 1203 1443
Profit After Tax 1551 1417 1254 1395 1042 1419 1510 1547 2401 2559 2835 3745
Adjustments -6 -28 -73 -35 -36 -9 18 -0 4 -43 -34 -36
Profit After Adjustments 1545 1388 1181 1360 1006 1411 1528 1547 2405 2517 2802 3709
Adjusted Earnings Per Share 19.2 17.3 14.7 16.9 12.5 17.5 19 19.2 29.8 31.2 34.7 45.9

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 5% 10% 8% 11%
Operating Profit CAGR 14% 16% 12% 9%
PAT CAGR 11% 22% 15% 6%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 45% 15% 19% 13%
ROE Average 13% 13% 12% 13%
ROCE Average 18% 18% 16% 15%

Cipla Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 9019 10050 10801 11516 12544 14229 15012 15763 18327 20842 23408
Minority's Interest 0 50 180 350 438 352 332 294 259 276 306
Borrowings 1 318 309 222 3645 3662 3830 2369 1203 416 0
Other Non-Current Liabilities 1024 1710 2108 1185 868 597 816 603 457 205 184
Total Current Liabilities 2278 2564 3881 7776 3374 3832 3772 4393 4591 4913 5033
Total Liabilities 12321 14692 17281 21049 20869 22673 23762 23423 24837 26652 29007
Fixed Assets 3610 6496 6830 9368 9490 9949 9547 9559 9394 9622 9101
Other Non-Current Assets 1927 2543 2860 2840 2574 1910 1789 2158 2234 2303 2631
Total Current Assets 6784 5652 7591 8841 8736 10814 12425 11704 13181 14711 16805
Total Assets 12321 14692 17281 21049 20869 22673 23762 23423 24837 26652 29007

Cipla Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 90 143 176 546 858 610 853 508 649 790 658
Cash Flow from Operating Activities 1398 1563 1173 1741 2382 1463 1691 3068 3755 3326 3238
Cash Flow from Investing Activities -2063 -1250 -941 -4523 -1310 -854 -1669 104 -2387 -1872 -2389
Cash Flow from Financing Activities 718 -266 165 3104 -1326 -385 -349 -2949 -1240 -1600 -958
Net Cash Inflow / Outflow 53 48 397 322 -254 223 -326 224 129 -146 -109
Closing Cash & Cash Equivalent 143 176 564 858 610 853 508 742 790 658 561

Cipla Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 19.24 17.29 14.71 16.93 12.51 17.52 18.96 19.18 29.82 31.19 34.71
CEPS(Rs) 23.43 22.29 21.91 26.76 29.4 34.06 35.2 33.76 43.02 44.76 49.65
DPS(Rs) 2 2 2 2 2 3 3 4 5 5 8.5
Book NAV/Share(Rs) 112.21 124.79 133.38 142.23 155.15 175.92 185.62 194.85 226.73 257.78 289.24
Core EBITDA Margin(%) 26.2 20.73 18.87 17.98 16.92 18.57 12.95 11.72 15.05 15.18 16.13
EBIT Margin(%) 25.38 19.69 15.91 14.02 9.44 11.72 9.4 8.76 12.22 12.11 13.41
Pre Tax Margin(%) 24.98 18.27 14.44 12.52 8.35 10.97 8.7 8.03 11.66 11.75 13.05
PAT Margin (%) 18.49 13.77 10.95 10.12 7.13 9.33 6.31 5.7 8.51 8.61 9.17
Cash Profit Margin (%) 22.43 17.39 15.36 15.59 16.17 18.02 11.86 10.03 12.29 12.15 12.95
ROA(%) 13.97 10.49 7.85 7.28 4.97 6.52 6.5 6.56 9.95 9.94 10.19
ROE(%) 18.64 14.89 12.1 12.61 8.72 10.65 10.37 10.09 14.13 13.1 12.85
ROCE(%) 24.15 19.05 15.33 13.24 8.28 10.2 11.94 12.53 17.85 17.24 18.19
Receivable days 70.11 58.66 57.94 57.62 61.36 67.94 55.36 54.1 47.44 42.19 44.13
Inventory Days 92.19 93.68 106.36 100.43 90.98 90.29 61.13 56.12 58.49 61.53 61.98
Payable days 93.96 85.15 103.91 104.98 104.58 123.84 128.32 128.84 107.95 98.28 109.8
PER(x) 19.74 22.19 48.36 30.26 47.35 31.01 27.91 22.05 27.34 32.65 25.95
Price/Book(x) 3.38 3.07 5.33 3.6 3.82 3.09 2.85 2.17 3.6 3.95 3.11
Dividend Yield(%) 0.53 0.52 0.28 0.39 0.34 0.55 0.57 0.95 0.61 0.49 0.94
EV/Net Sales(x) 3.78 3.13 5.13 3.35 3.55 3.09 2.83 2.1 3.45 3.72 3.15
EV/Core EBITDA(x) 12.94 13.29 25.03 16.92 18.91 14.72 12.97 10.12 14.63 16.77 13.02
Net Sales Growth(%) 17.93 22.88 11.52 19.83 5.88 5.29 7.96 4.7 11.84 13.59 4.55
EBIT Growth(%) 43.27 -4.86 -10.03 6.1 -28.55 29.11 26.01 5.69 45.26 4.31 15.23
PAT Growth(%) 35.9 -8.67 -11.47 11.26 -25.3 36.16 6.36 2.48 55.23 6.59 10.78
EPS Growth(%) 35.01 -10.13 -14.96 15.11 -26.1 40.05 8.23 1.16 55.46 4.61 11.28
Debt/Equity(x) 0.11 0.12 0.16 0.46 0.33 0.29 0.29 0.18 0.1 0.04 0.02
Current Ratio(x) 2.98 2.2 1.96 1.14 2.59 2.82 3.29 2.66 2.87 2.99 3.34
Quick Ratio(x) 1.96 1.09 0.99 0.65 1.56 1.77 2.24 1.67 1.85 1.91 2.31
Interest Cover(x) 62.79 13.9 10.83 9.36 8.67 15.61 13.34 12.04 21.47 33.85 37.87
Total Debt/Mcap(x) 0.03 0.04 0.03 0.13 0.09 0.09 0.1 0.08 0.03 0.01 0.01

Cipla Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 35.92 33.42 33.42 33.41 33.41 33.41 33.4 33.4 33.4 33.4
FII 24.23 26.48 27.48 27.52 28.21 27.29 25.44 25.69 25.68 25.77
DII 21.42 21.87 21.22 21.56 20.96 21.96 24.22 24.06 24.22 24.3
Public 17.92 17.62 17.3 16.91 16.81 16.92 16.73 16.64 16.5 16.32
Others 0.52 0.61 0.59 0.6 0.61 0.42 0.2 0.21 0.21 0.21
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 33.4%.
  • Company has a low return on equity of 13% over the last 3 years.
  • Debtor days have increased from 98.28 to 109.8days.
  • Stock is trading at 4.2 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Cipla News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!